Adam Drobnis, MD
Neurology · Warwick, RINPI 1457583387
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 204 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by AbbVie at 31.7% of the total. 2025 is the largest year on record at $1,858, 2.8 times the $658 reported in 2023.
Across 204 payments — averaging $20.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Lundbeck LLC$917
- Pfizer$703
- Teva Pharmaceuticals USA, Inc.$506
- SK Life Science, Inc.$146
- Lilly USA, LLC$131
- plus $488 from 10 others
What the payments were for
- Food & beverage$4,232100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 79 | $1,342 |
| Lundbeck LLC | 34 | $917 |
| Pfizer | 35 | $703 |
| Teva Pharmaceuticals USA, Inc. | 21 | $506 |
| SK Life Science, Inc. | 6 | $146 |
| Lilly USA, LLC | 7 | $131 |
| EMD Serono, Inc. | 5 | $106 |
| Axsome Therapeutics, Inc. | 4 | $89 |
| Amgen | 4 | $81 |
| Vanda Pharmaceuticals Inc. | 2 | $47 |
| AstraZeneca | 2 | $43 |
| MDD US Operations, LLC | 1 | $31 |
| UCB, Inc. | 1 | $28 |
| Scilex Pharmaceuticals Inc. | 1 | $24 |
| Insightec,inc | 1 | $20 |
| Biogen | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,232 in reported general payments places this provider in the 70th percentile of 86 neurology providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Aimovig AutoinjectorErenumab-Aooe | 23 | $16,326 |
| Gabapentin | 108 | $2,721 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 76 | $2,031 |
| Propranolol Hcl ErPropranolol Hcl | 15 | $1,705 |
| Memantine Hcl | 31 | $1,614 |
| Donepezil Hcl | 95 | $1,164 |
| Levetiracetam | 31 | $967 |
| Sumatriptan Succinate | 46 | $790 |
| Lamotrigine | 12 | $752 |
| Amitriptyline Hcl | 39 | $466 |
| Propranolol Hcl | 15 | $310 |
| Topiramate | 47 | $292 |
| Primidone | 11 | $197 |
| Baclofen | 12 | $192 |
| Carbamazepine | 14 | $155 |
Paid to pharmacies, not to this prescriber.
Other neurology in Warwick
- Arshad IqbalWarwick$21K
- Gary LeuropaWarwick$7K
- Keith BrecherWarwick$4K
- Mauricio VillamarWarwick$798
- Stephen SallowayProvidence$329K
- Peter BellafioreWakefield$274K
- Norman GordonEast Providence$206K
- Syed RizviProvidence$160K
- Albert MaranoJohnston$145K
- John EastonProvidence$112K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.